All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 3rd European Myeloma Network Meeting, the Multiple Myeloma hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How is the definition of high-risk multiple myeloma (MM) evolving?
How is the definition of high-risk MM evolving?
Paiva begins by explaining how the evolution of defining high-risk MM has been positive over the past few decades, which could lead to significant improvements in how patients are staged in the future. The starting point for defining high-risk MM is a Revised International Staging System (R-ISS) Stage 3. Paiva states that this is effective; however, there is room for improvement, either by increasing the accuracy of risk stratification at baseline or after treatment, for example by assessing additional cytogenetic abnormalities, analyzing tumor burden, and evaluating minimal residual disease.
Could CTCs and tumor DNA be more sensitive than a BM aspirate to assess treatment response in MM?
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We...
How significant is the role of MRD status in MM, and how can we best utilize this information?
At ASH 2019, Bruno Paiva, University of Navarra, Pamplona, ES, answers the question: How significant is the role of minimal residual disease status in...
Subscribe to get the best content related to multiple myeloma delivered to your inbox